Muscular Dystrophy: Exon Skipping Shows Dramatic Effects In Preventing, Treating Muscle-wasting Disease In Mice Oct 22, 2009
UWA Professor Steve Wilton, head of the Molecular Genetic Therapies Group at UWA's Centre for Neuromuscular and Neurological Disorders, was part of a team which included researchers at The University of Oxford and biotech company AVI BioPharma. The research, published in the journal Molecular Therapy, has demonstrated that a process known as exon skipping has shown dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe... (Science Daily)
AVI BioPharma gets $11M military contract Oct 6, 2009
AVI BioPharma gets $11 ... AVI BioPharma gets $11 ... The TMTI was created by the U.S. Dept. of Defense to study ways to protect soldiers from biological threats by developing medical countermeasures, such as those created by Bothell-based AVI BioPharma (NASDAQ: AVII), which recently moved its headquarters from Oregon. (Puget Sound Business Journal, WA)
AVI BioPharma loses $19.7M in Q2 Aug 11, 2009
AVI BioPharma loses $19 ... AVI BioPharma loses $19 ... The increase or decrease in the warrant liability fluctuates as the price of the company s stock fluctuates, AVI BioPharma said. (Puget Sound Business Journal, WA)
Corvallis biotech firm to move R&D, headquarters to Seattle (110) Jul 31, 2009
Corvallis-based biotech firm AVI Biopharma announced Thursday that it intends to move and expand its research and development departments in Seattle, drawing about 15 jobs from the mid-valley in the process. CEO Leslie Hudson said the company s work on anti-viral drugs for the military will remain in Corvallis, along with. (Corvallis Gazette Times, OR)
Semi-Annual Changes to the NASDAQ Biotechnology Index May 9, 2009
As a result of the re-ranking, ACADIA Pharmaceuticals, Inc. (NasdaqGM: - ), Altus Pharmaceuticals, Inc. (NasdaqGM: - ), Angiotech Pharmaceuticals, Inc. (NasdaqGS: - ), AVI BioPharma, Inc. (NasdaqGM: - ), Caliper Life Sciences, Inc. (NasdaqGM: - ), Cell Genesys, Inc. (NasdaqGM: - ), Cerus Corporation (NasdaqGM: - ), CombinatoRx, Inc. (NasdaqGM: - ), Eurand, N.V. (NasdaqGM: - ), GenVec, Inc. (NasdaqGM: - ), Harvard Bioscience, Inc. (NasdaqGM: - ), Hi-Tech Pharmacal Co., Inc. (NasdaqGS: - ),... (Primezone Releases)
» Swine flu fears a boon? Apr 29, 2009
-based AVI Biopharma Inc., which develops treatments for viral infections. The stock rose 16 cents, or 18 percent, to $1. (Northwest Indiana Times)
Submit your picks for family business awards Mar 17, 2009
AVI BioPharma Inc.: David J. Boyle II, chief financial officer, purchased 19,000 shares at 64 cents each on March 13 and now directly and indirectly holds 65,282. NORTHWEST. (OregonLive, OR -- Business)
